RecruitingNCT06564974
Registry Study to Observe Long-term Safety of Vamorolone (AGAMREE®) in Patients With Duchenne Muscular Dystrophy-SUMMIT
Studying Duchenne muscular dystrophy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Catalyst Pharmaceuticals, Inc.
- Principal Investigator
- William Andrews, MDCatalyst Pharmaceuticals
- Intervention
- Vamorolone(drug)
- Enrollment
- 250 enrolled
- Eligibility
- 2 years · MALE
- Timeline
- 2024 – 2032
Study locations (27)
- Phoenix Children's Hospital, Phoenix, Arizona, United States
- Arkansas Childrens Hospital, Little Rock, Arkansas, United States
- Children's Hospital Los Angeles, Los Angeles, California, United States
- Stanford University, Palo Alto, California, United States
- University of California, Davis, Sacramento, California, United States
- University of Florida Clinical and Translational Science Institue, Gainesville, Florida, United States
- Nicklaus Children's Hospital, Miami, Florida, United States
- Nemours Children's Hospital, Orlando, Florida, United States
- Johns Hopkins All Children's Hospital, St. Petersburg, Florida, United States
- Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
- Indiana University Health - Riley Hospital for Children, Indianapolis, Indiana, United States
- University of Kansas Medical Center, Kansas City, Kansas, United States
- University of Massachusetts Memorial Medical Center, North Worcester, Massachusetts, United States
- Helen DeVos Children's Hospital, Grand Rapids, Michigan, United States
- Atrium Health Neurosciences Institute, Charlotte, North Carolina, United States
- +12 more locations on ClinicalTrials.gov
Collaborators
ICON Medical Imaging · ICON plc · Veeva Systems · Children's Hospital of Eastern Ontario · Medpace, Inc.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06564974 on ClinicalTrials.govOther trials for Duchenne muscular dystrophy
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07332013Urinary Titin Biomarker in DMDChildren's Hospital of Philadelphia
- RECRUITINGNCT07092540The Baby Duchenne Study: Characterizing Developmental and Clinical Outcomes in the First Three Years in Children With Duchenne Muscular DystrophyUniversity of Rochester
- ENROLLING BY INVITATIONNANCT06887491The Effect of Dual-tasking Program on Cognitive and Physical Functions and Independence in Activities of Daily Living in Children With Duchenne Muscular Dystrophy: A Single-blind Randomized Controlled TrialLokman Hekim University
- ACTIVE NOT RECRUITINGPHASE1NCT07347548A Trial to Investigate the Safety and Pharmacokinetics of GRT6019 in Healthy Male ParticipantsGrünenthal GmbH
- ENROLLING BY INVITATIONPHASE2NCT07209332Open-Label Extension Study of WVE-N531 in Patients With Duchenne Muscular DystrophyWave Life Sciences Ltd.
- ACTIVE NOT RECRUITINGEARLY PHASE1NCT07282652A Study to Evaluate the Safety and Tolerability of RAG-18 in Pediatric Patients With Duchenne Muscular DystrophyPeking Union Medical College Hospital
- RECRUITINGPHASE2NCT07287189Phase 2 Study of SAT-3247 in Pediatric Ambulatory PatientsSatellos Bioscience, Inc.
- ENROLLING BY INVITATIONNCT07435116Duchenne Muscular Dystrophy and the Viscoelastic Properties of Upper Limb MusclesSanko University